Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Diabetes and Endo
    • SGLT2 inhibitor...

    SGLT2 inhibitor canagliflozin reduces gout flares in type 2 diabetes: CANVAS Program

    Written by Medha Baranwal Baranwal Published On 2019-12-17T20:28:04+05:30  |  Updated On 23 Aug 2021 4:27 PM IST

    Delhi: Canagliflozin (Invokana) -- a medication used for the treatment of type 2 diabetes (T2D) -- lowered serum urate and reduced the risk of gout flare in T2D patients, finds a recent study published in The Lancet Rheumatology. The study was a post-hoc analysis of data from two large clinical trials -- CANVAS and CANVAS-Renal -- that assessed the cardiovascular and renal safety of canagliflozin compared with placebo in patients with type 2 diabetes.


    Gout is a metabolic disorder characterized by increased uric acid in the blood and the deposition of amorphous urate crystals that cause a vigorous inflammatory reaction in the joints, kidneys, and soft tissues. It is characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in the joints, often the joint at the base of the big toe. Gout symptoms may come and go, but there are ways to manage symptoms and prevent flares.


    Management of gout remains poor, reflecting inadequate urate-lowering therapy doses, poor adherence, and insufficient therapeutic options for patients who are unable to take or have inadequate responses to available therapies. Patients with gout often have numerous comorbidities that require additional medications, adding complexity to their medication regimen.


    Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that increases urinary glucose excretion and improves glycemic control, weight control, albuminaria and blood pressure in T2D patients. Treatment with canagliflozin reduces serum urate concentration in patients with type 2 diabetes with similar effects observed for other SGLT2 inhibitors. However, there is no information on whether SGLT2 inhibitors protect against gout.


    The current CANVAS clinical trial program by Prof Bruce Neal, University of New South Wales, Sydney, Australia, and colleagues aimed to investigate the effect of canagliflozin compared with placebo on gout.


    In the CANVAS Program, people with type 2 diabetes and an elevated risk of cardiovascular disease were randomly assigned to receive either canagliflozin (100 or 300 mg) or placebo.



    10 142 participants were included in analyses. At baseline, mean age was 63 years (SD 8), 3633 (36%) participants were female, mean serum urate concentration was 348·9 μmol/L (95·5), and 471 (5%) of participants had a history of gout.


    Read Also: FDA approves canagliflozin to treat diabetic kidney disease in type 2 diabetes patients


    Key findings of the study include:


    • Mean follow-up was 3·6 years (SD 2·0) and mean serum urate concentration was −23·3 μmol/L lower in participants treated with canagliflozin than in those who received placebo, equating to a 6·7% reduction in serum urate.

    • During follow-up, 80 individuals reported an episode of gout flare and 147 commenced a drug for gout.

    • The occurrence of gout flare or the need for treatment for gout was lower in participants treated with canagliflozin than in those who received a placebo (HR 0·53).

    • The proportional reduction for gout flare adverse events (2·0 patients with an event per 1000 patient-years in the canagliflozin group vs 2·6 patients with an event per 1000 patient-years in the placebo group; 0·64) was similar in size to that for commencement of a drug for gout (3·3 vs 5·4 patients with an event per 1000 patient-years; 0·52) and hyperuricemia (1·8 vs 2·5 patients with an event per 1000 patient-years; 0·59).


    Read Also: Canagliflozin not only lowers blood sugar but also reduces kidney failure risk in Diabetes


    "This agent (canagliflozin) appears to show potential for being a dual-benefit gout therapy, lowering serum urate and providing potential flare prophylaxis and thereby potentially reducing the need for separate flare prophylaxis with agents that are often contraindicated or poorly tolerated in patients with gout," Tuhina Neogi, Boston University School of Medicine, Boston, MA, USA, wrote in an accompanying comment.



    The study, "The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program," is published in The Lancet Rheumatology.

    DOI: https://doi.org/10.1016/S2665-9913(19)30078-5

    Bruce NealCanagliflozinCANVAS trialgout flareInvokanaLancet RheumatologyType-2 diabetesurate
    Source : The Lancet Rheumatology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok